Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed in the UK for weight management, working by mimicking natural appetite-regulating hormones
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
A provider who explains this reasoning clearly tends to leave patients with a more realistic sense of what a supervised plan actually involves
**The listing of a company (e.g., Novo Nordisk, Eli Lilly) or product (e.g., Ozempic, Mounjaro, Wegovy, Rybelsus, Trulicity, Saxenda or Zepbound) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective
Contact us and schedule a consultation today!